Farhat Akram, Abou-Karroum Rime, Panchaud Alice, Csajka Chantal, Al-Hajje Amal
Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.
Curr Ther Res Clin Exp. 2021 Oct 28;95:100650. doi: 10.1016/j.curtheres.2021.100650. eCollection 2021.
It has been well recognized that pharmaceutical interventions (PIs) can prevent patient harm related to prescribing errors. Various tools have been developed to facilitate the detection and the reduction of inappropriate prescriptions and some have shown benefit on clinical outcomes.
The objective of this study was to evaluate the clinical, economical, and organizational impact of interventions generated by clinical pharmacists in hospitalized patients, and to evaluate the performance of an explicit tool, the Potentially Inappropriate Medication Checklist for Patients in Internal Medicine (PIM-Check), in detecting each pharmacist's intervention.
A cohort retrospective study was conducted on hospitalized patients. The impact of PIs based on pharmacists' standard examination was evaluated using the Clinical, Economic, and Organizational (CLEO) tool. The performance of PIM-Check in detecting each intervention was assessed by conducting a retrospective medication review based on available information collected from patients' records. A qualitative analysis was also conducted to identify the types of PIs that PIM-Check failed to detect.
The study was performed on 162 patients with a median age of 68 years (interquartile range = 46-77 years) and a median hospital stay of 5 days (interquartile range = 4-7 days). The pharmacists generated 1.9 PIs per patient (n = 304) of which 31% were detected by PIM-Check. The acceptance rate of the interventions by physicians was 84% (n = 255). Among the accepted interventions, 53% (n = 136) had a clinical impact graded CL ≥ 2C (moderate or major), whereas the majority of them were not detected by PIM-Check (63%; 86 out of 136). In addition, 46% of accepted interventions (n = 117) were associated with a cost decrease, among which 62% were not detected by PIM-Check (73 out of 117). The qualitative analysis shows that PIM-Check mostly failed to detect PIs related to dose adjustment, overprescribing, and therapy monitoring.
According to the CLEO tool evaluation of PIs, our results show that clinical pharmacists' interventions are associated with improved clinical outcomes. In comparison with pharmacists' interventions, PIM-Check failed in detecting the majority of interventions associated with a moderate or major impact.
人们已经充分认识到药物干预(PIs)可以预防与处方错误相关的患者伤害。已经开发了各种工具来促进不适当处方的检测和减少,并且一些工具已显示出对临床结果有益。
本研究的目的是评估临床药师对住院患者进行干预所产生的临床、经济和组织影响,并评估一种明确的工具——内科患者潜在不适当用药清单(PIM-Check)在检测每位药师干预措施方面的性能。
对住院患者进行队列回顾性研究。使用临床、经济和组织(CLEO)工具评估基于药师标准检查的药物干预的影响。通过根据从患者记录中收集的可用信息进行回顾性用药审查,评估PIM-Check在检测每种干预措施方面的性能。还进行了定性分析,以确定PIM-Check未能检测到的药物干预类型。
该研究对162例患者进行,中位年龄为68岁(四分位间距=46-77岁),中位住院时间为5天(四分位间距=4-7天)。药师为每位患者产生1.9次药物干预(n=304),其中31%被PIM-Check检测到。医生对干预措施的接受率为84%(n=255)。在接受的干预措施中,53%(n=136)具有分级为CL≥2C(中度或重度)的临床影响,而其中大多数未被PIM-Check检测到(63%;136例中的86例)。此外,46%的接受干预措施(n=117)与成本降低相关,其中62%未被PIM-Check检测到(117例中的73例)。定性分析表明,PIM-Check大多未能检测到与剂量调整、处方过量和治疗监测相关的药物干预。
根据CLEO工具对药物干预的评估,我们的结果表明临床药师的干预与改善临床结果相关。与药师的干预相比,PIM-Check未能检测到大多数具有中度或重度影响的干预措施。